Fertility Test Market to Flourish at 7.2% CAGR to 2023 - Key Trends and Industry Insights

PUNE, India, July 20, 2018 /PRNewswire/ --

ReportsnReports.com adds the global fertility test market is projected to reach USD 583.1 million by 2023 from USD 411.8 million in 2018, at a CAGR of 7.2%. Growth in the fertility test market can be attributed to factors, such as increasing first-time pregnancy age, launch of advanced, easy-to-use fertility monitors with high accuracy, and increasing awareness about fertility testing.

Browse 71 Market Data Tables and 31 Figures spread through 140 Pages and In-depth TOC on "Fertility Test Market by Product (Ovulation Predictor Kits, Fertility Monitors (Urine & Saliva-based)), Mode of Purchase (OTC, Prescription), Application (Female, Male), End User (Home care, Fertility clinics, Hospital) - Global Forecast to 2023" at http://www.reportsnreports.com/reports/1571496-fertility-test-market-b ... .

SPD Swiss Precision Diagnostics (Switzerland), Church & Dwight (US), & Prestige Brands Holdings (US) held the leading position in fertility test market. These companies adopted product launches, enhancements, and acquisitions as their key growth strategies in the past three years. include Valley Electronics (Germany), Geratherm Medical (Germany), Hilin Life Products (US), Fairhaven Health (US), Fertility Focus (UK), bioZhena (US), TaiDoc Technology (Taiwan), UEBE Medical (Germany), AdvaCare Pharma (US), Ava (Switzerland), Babystart (UK), and Sensiia (UK) are some of the other major players operating in this market.

Stakeholders 

• Fertility testing devices manufacturing companies
• Distributors, suppliers, and commercial service providers
• Fertility clinics
• Research laboratories and academic institutes
• Market research and consulting firms

Geographically, fertility test market segmented into North America, Europe, Asia Pacific (APAC), & Rest of the World. The APAC market is expected to register highest growth rate during forecast period. Fast growth of this segment is mainly due to growing number of women suffering from lifestyle disorders, increasing healthcare expenditure in these regions, rising funding/investments for the development of fertility and ovulation monitors.